Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S- and M-phase cyclins and p21(CIP1) expression.

Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S- and M-phase cyclins and p21(CIP1) expression. Oncol Lett. 2017 Oct;14(4):4237-4242 Authors: Du C, Wang Y, Li H, Huang Y, Jiang O, You Y, Luo F Abstract Radiotherapy and adjuvant chemotherapy have become the standard treatments for multiple types of cancer. Although cancer cells are usually sensitive to radiotherapy, metastasis and local failure still occur mainly due to developed resistance to radiotherapy. Thus, it is critical to improve therapeutics for cancer treatment. The present study demonstrated that third-generation bisphosphonate zoledronic acid (ZOL), even at a low concentration, augments the radiosensitivity of cancer cells exposed to ionizing radiation (IR) by inducing S-phase arrest and subsequently promoting apoptosis. This function of ZOL was associated with elevated levels of cyclin A and cyclin B in the S and M phases, as well as decreased p21(CIP1) expression. In addition, ZOL also inhibited malignant the invasiveness of cancer cells. Notably, these effects could be enhanced concurrently with IR. The present data indicated that combined treatment with ZOL plus IR may be a novel technique to augment the radiosensitivity of cancer cells. PMID: 28943933 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research